Shares of Cidara Therapeutics Inc (NASDAQ:CDTX) have been assigned an average rating of “Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $14.28.
Several equities analysts have issued reports on CDTX shares. Zacks Investment Research lowered shares of Cidara Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 12th. Cantor Fitzgerald set a $15.00 price target on shares of Cidara Therapeutics and gave the stock a “buy” rating in a report on Tuesday, November 28th. Finally, HC Wainwright lifted their price target on shares of Cidara Therapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, November 9th.
Several large investors have recently bought and sold shares of CDTX. Prosight Management LP acquired a new stake in shares of Cidara Therapeutics during the fourth quarter worth $11,206,000. Goldman Sachs Group Inc. acquired a new stake in shares of Cidara Therapeutics during the second quarter worth $650,000. Eversept Partners LLC acquired a new stake in shares of Cidara Therapeutics during the fourth quarter worth $340,000. Renaissance Technologies LLC lifted its stake in shares of Cidara Therapeutics by 26.2% during the fourth quarter. Renaissance Technologies LLC now owns 179,300 shares of the biotechnology company’s stock worth $1,219,000 after buying an additional 37,197 shares during the period. Finally, Broadfin Capital LLC lifted its stake in shares of Cidara Therapeutics by 4.5% during the fourth quarter. Broadfin Capital LLC now owns 857,397 shares of the biotechnology company’s stock worth $5,830,000 after buying an additional 36,994 shares during the period. Institutional investors and hedge funds own 55.58% of the company’s stock.
WARNING: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.com-unik.info/2018/02/17/brokerages-set-cidara-therapeutics-inc-cdtx-price-target-at-14-28.html.
About Cidara Therapeutics
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.